otq923
otq923: 1 clinical trial tracked.
otq923 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about otq923, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Primary endpoint: Number of participants with delayed adverse events that are suspected to be related to previous OTQ923 therapy
Interventionalopen4 enrolledStarted 2024-04Completion 2039-013 sites · United StatesNovartis Pharmaceuticals